MedPath

The Predictive Value of Transcutaneous VNS for Effect of an Implanted VNS System in Epilepsy Patients

Completed
Conditions
neurologische aandoeningen, hersenaandoeningen, epilepsie
epilepsy
epileptic seizure
Registration Number
NL-OMON42025
Lead Sponsor
Medisch Spectrum Twente
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

Age >= 18 years
Diagnosed with epilepsy
Stable epilepsy
Scheduled for an implantable VNS system
Able to read and understand Dutch
Physically and cognitively capable of using the tVNS device and participating in the measurements

Exclusion Criteria

severe cognitive impairment(s)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The predictive value of tVNS for the effects of the implantable VNS system.<br /><br>Positive effects of the VNS system are seizure frequency reduction, seizure<br /><br>intensity reduction, seizure duration reduction (obtained from patient*s<br /><br>seizure diary (NHS3 clinician rated scale)) and improvement in quality of life<br /><br>(QOLIE 31P) or mood (MADRS). Correlations between these effects and effects of<br /><br>tVNS will be evaluated. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The effects of 6 weeks and 3 months of tVNS and the effects of 3, 6, 9 and 12<br /><br>months of implanted VNS will be evaluated by measuring a broad set of<br /><br>parameters as described in the protocol (Chapter 3).</p><br>
© Copyright 2025. All Rights Reserved by MedPath